Volume 11, Issue 2, June 2007
From the Coordinator
SIG Members Seek Networking and Credentialing Opportunities

Jennifer Loud, RN, MSN, CRNP

At the SIG Planning/Networking Meeting at the 32nd Annual Congress, we welcomed Lisa Aiello-Laws, RN, MSN, APN-C, AOCNS, APNG, as the newly elected Cancer Genetics SIG coordinator-elect. Congratulations, Lisa!

Lisa is a certified advanced practice oncology nurse and an advanced practice nurse in genetics. She is the manager of the cancer program at Shore Memorial Hospital Cancer Center in Somers Point, NJ. She brings a wealth of experience and expertise to the position, and I’m certain that the Cancer Genetics SIG will benefit from her leadership. I look forward to working with Lisa on new initiatives for the Cancer Genetics SIG this year and to a smooth transition in leadership over the years to come. As always, research results from the past year have led to changes in how we practice and educate our patients. By integrating new cancer screening and prevention recommendations into clinical practice, or by delivering new gene-targeted drugs to our patients, we constantly uphold the challenge of staying abreast of new evidence-based practice guidelines in clinical cancer genetics and integrating them into our practice when appropriate.

In this issue, Cancer Genetics SIG member Carol Cherry, MSN, RN, C, OCN®, discusses ovarian cancer risk-reducing surgery in an article about a resource that she and her colleagues from the Family Risk Assessment Program at Fox Chase Cancer Center in Philadelphia, PA, published this year. Having used the strategy in my own patient populations, I can attest to the quality and usefulness of the decision-making tool for women who are at high genetic risk of being diagnosed with ovarian cancer and are considering ovarian cancer risk-reducing surgery.

Cancer Genetics SIG member Becky Althus, RN, PhD, CGC, contributed an article on the ethics of providing care to individuals who are at high genetic risk of cancer and reminds us of the benefits, risks, and dilemmas that can occur while caring for that special patient population. This issue introduces a new section, "News to Use," from the National Institutes of Health (NIH) and National Cancer Institute (NCI). "News to Use" will provide summaries of press releases from NIH and NCI that pertain to cancer genetics. Let us know if they are useful to you. The full press releases are available on the NIH or NCI Web site, and the link for each topic is provided.

Many members have interest in a list serve for the Cancer Genetics SIG to facilitate discussions about membership. To remind everyone, the Cancer Genetics SIG’s page on the SIGs Virtual Community is available for that specific purpose, although the page currently does not have an administrator. If anyone in the Cancer Genetics SIG is interested in being trained as an administrator for the Virtual Community, please e-mail me at loudj@mail.nih.gov. The training does not take a lot of time.

Some members also have expressed interest in cancer genetics credentialing. Currently, no specific certification or credentialing is available in clinical cancer genetics for nurses (if someone knows differently, please contact me), although the International Society of Nurses in Genetics offers two credentials for nurses in genetics. The Genetic Nursing Credentialing Commission provides recognition for clinical nursing practice in health care with a genetics component. Nurses who have a master’s degree in nursing may qualify for the advanced practice nurse in genetics (APNG) credential, and those with a bachelor’s degree in nursing may qualify for the genetics clinical nurse (GCN) credential. Additional information about the credentialing process is available at http://www.isong.org/resources/credentialing.cfm.

I would like to thank the Cancer Genetics SIG Newsletter team: Millie Arnold, RN, OCN®, CCRC, newsletter editor; Patricia Kelly, RN, MS, AOCN®, co-editor; and Patricia Herman, MSN, RN, AOCN®, co-editor, for all of the time, dedication, and energy they have graciously volunteered this year to publish three newsletters. They deserve our thanks and congratulations!

The Camcer Genetics SIG Newsletter is produced by members of the
Cancer Genetics SIG and ONS staff and is not a peer-reviewed publication.

Special Interest Group Newsletter  June 2007

Ovarian Cancer Risk-Reducing Surgery: A Decision-Making Resource

Carol Cherry, MSN, RN, C, OCN®

The Family Risk Assessment Program at Fox Chase Cancer Center in Philadelphia, PA, published Ovarian Cancer Risk-Reducing Surgery: A Decision-Making Resource in September 2006. The project to develop the resource spanned several years and was a direct outgrowth of a void in educational materials on the topic of decision-making for risk-reducing surgery. Cancer genetics professionals, who counsel women considering elective removal of their ovaries, understand the complexity of the decisions they face. Understanding the extent of risk for ovarian cancer, weighing the timing of ovary removal, and choosing among various surgical options all need to be explored. Also, the implications of surgically induced menopause (in women who are premenopausal) and the impact on sexuality and intimate relationships are very important.

Development of the book was a collaborative, interdisciplinary effort that included input from 10 oncology nurses. The Fox Chase team conducted focus groups with women and their partners who had faced such decisions. Their input guided the book’s content, and many quotations of their actual experiences are found throughout. More than 20 lay and professional reviewers provided feedback, which led to revisions.

The book is divided into five sections.
  • Understanding your risk of ovarian cancer
  • Considering risk-reducing surgery
  • If you want to have risk-reducing surgery: what you need to know
  • If you do not want to have surgery now: what you need to know
  • Sexuality and intimate relationships after risk-reducing surgery

Each section ends with a list of questions to discuss with a healthcare team, and numerous resources for further information are provided. Also included is a section where women can write their personal preferences as part of the decision-making process.

The development of the book and the printing of 2,000 copies were funded by the Sandy Rollman Ovarian Cancer Foundation, Inc. Books were made available free of charge and circulated through various professional and advocacy channels, such as the National Society of Genetic Counselors, the International Society of Nurses in Genetics (ISONG), the National Ovarian Cancer Coalition (NOCC) Philadelphia Chapter, the Ovarian Cancer National Alliance, and Facing Our Risk of Cancer Empowered.

Copies of the book were sent to genetics professionals and women at risk throughout the United States, Canada, England, and Slovenia. After only three months, a second printing was needed. An additional 2,500 copies soon will be available thanks to generous funding from the NOCC Philadelphia Chapter.

Feedback has been extremely positive. Professionals who requested a single copy are now requesting quantities ranging from 10–200 copies. An online version of the book will be available soon. The book was featured in a presentation on the use of decision aids in genetic health care at the 20th Annual ISONG Conference in May in Bristol, England, and will be distributed to an international audience of genetics professionals.

The book is available free of charge. To obtain a copy, e-mail surgerybook@fccc.edu. Include your name, mailing address, number of copies needed, and your reason for requesting the resource.

Back to SIG Newsletter front page

Special Interest Group Newsletter  June 2007

Anticipate Ethical Issues in Genetic Testing

Becky Althaus, RN, PhD, CGC

As testing for hereditary predisposition cancer genes is used more in comprehensive oncology care, ethical issues may provide nurses with new dilemmas to solve. As with all medical care, the basic principles of ethical care are beneficence, nonmaleficence, autonomy, and justice. The most common genes that cause increased probability of cancer are BRCA1 and BRCA2, which are associated with breast and ovarian cancer; and MLH1, MSH2, and MSH6, which are associated with colon, endometrial, and ovarian cancer.

Beneficence, the ethical principle to do good, and nonmaleficence, the principle to do no harm, are linked closely in clinical care. With genetic testing, providing information to one individual may result in psychological harm to another family member. Some situations may reveal that family relationships are not what they appear to be. Nonpaternity can be determined by testing several family members for genetic mutations. However, that can result in harm to a family, with psychological and sociologic consequences.

In some cases, people may not want to know their own carrier status of a damaging mutation. In genetic testing for predisposition cancer genes, genetic counseling and discussions are administered to ensure that patients want to know their genetic status and are prepared for possible diagnoses. However, when an individual’s offspring carries the same mutation found in an aunt, uncle, sibling, or grandparent, the parent can deduce that he or she also carries the mutation. Therefore, without personal testing, people may learn genetic status without wanting such knowledge, which can result in feelings of sadness, anger, guilt, and fear. In a similar situation, if one member of a pair of identical twins is tested, genetic makeup of both twins is determined, even if one of the pair does not want to know genetic status. Knowledge of genetic makeup could be detrimental to the twin who did not want to know. Autonomy, or ability of an individual to make decisions about genetic testing, can be removed by family testing in some situations. Nurses must be sensitive to family dynamics and help patients think through the issues with anticipatory guidance.

Justice is the principle that services are provided to all people in need, regardless of financial status or racial or ethnic heritage. Overall, in the United States, the vast majority of people obtaining genetic testing for BRCA1 and BRCA2 are Caucasian. Only 2.8% of those tested are African American (12.6% of the population), 3.5% are Hispanic (12.5% of the population), and 2% are Asian (4% of the population). Socioeconomic inequality and lack of health insurance are inadequate to explain the low uptake in testing of minorities. Little research has been undertaken to understand the small numbers of minority patients undergoing genetic testing. Clearly, genetic predisposition testing is not becoming available to people of minority heritage at the same level as for people of Caucasian heritage, resulting in a lack of justice nationwide.

Beneficence, nonmaleficence, autonomy, and justice are medical ethical principles that provide intriguing frameworks in the provision of testing for predisposition cancer genes. Unpredictable new ethical dilemmas are revealed as more and more people make use of new technology.

Back to SIG Newsletter front page

Special Interest Group Newsletter  June 2007

Essential Nursing Competencies and Curricula Guidelines for Genetics and Genomics

Lisa Aiello-Laws, RN, MSN, APN, C, APNG, AOCNS


Health care has changed dramatically with the mapping of the human genome. Genetics and genomics play a crucial role in the prevention and treatment of illnesses. Hereditary syndromes, pharmacogenomics, and targeted therapies have become major foci of clinical care. Regardless of specialty, practice setting, or role, genetic and genomic nursing competencies have become a necessity.

Historically, nursing curricula have not included genetic education. A consensus panel was formed to identify genetic competencies needed by all nurses in the United States. A steering committee first reviewed recommended practice in peer-reviewed literature. The recommendations were developed into a document, reviewed by nurse representatives from the National Coalition for Health Professional Education in Genetics, and posted by the American Nurses Association for public comment. Finally, consensus was obtained and achieved by key nursing stakeholders from professional organizations and accrediting organizations. First, two key definitions were defined. Genetics: the study of individual genes and their impact on relatively rare single gene disorders. Genomics: the study of every gene in the human genome together, including their interactions with each other, the environment, and other psychosocial and cultural factors. Competencies were divided into two domains: professional responsibilities and professional practice.

Professional Responsibilities
  • Recognize one’s own attitudes and values related to genetic and genomic science.
  • Advocate for clients’ access to genetic and genomic services and resources.
  • Examine competency of practice on a regular basis, identifying areas of strength, along with areas of needed growth.
  • Incorporate genetic and genomic technologies and information into RN practice.
  • Demonstrate in practice the importance of tailoring genetic and genomic information and services to clients based on their culture, religion, knowledge level, literacy, and preferred language.
  • Advocate for the rights of clients for autonomous, informed genetic- and genomic-related decision-making and voluntary action.
Professional Practice


The RN
  • Demonstrates an understanding of the relationship of genetics and genomics to health, prevention, screening, diagnostics, prognostics, selection of treatment, and monitoring of treatment effectiveness.
  • Demonstrates ability to elicit a minimum of three generations of family health history information.
  • Constructs a pedigree using standardized symbols and terminology.
  • Collects personal, health, and developmental histories that consider genetic, environmental, and genomic influences and risks.
  • Conducts comprehensive health and physical assessments that incorporate knowledge about genetic, environmental, and genomic influences and risk factors.
  • Critically analyzes the history and physical assessment findings for genetic, environmental, and genomic influences and risk factors.
  • Assesses clients’ knowledge, perceptions, and responses to genetic and genomic information.
  • Develops a plan of care that incorporates genetic and genomic assessment information.
Provision of Education, Care, and Support

The RN
  • Provides clients with interpretation of selective genetic and genomic information or services.
  • Provides clients with genetic and genomic credible, accurate, appropriate, and current information, resources, services, and technologies that facilitate decision making.
  • Uses health-promotion and disease-prevention practices that
    • Consider genetic and genomic influences on personal and environmental risk factors.
    • Incorporate knowledge of genetic and genomic risk factors.
  • Uses genetic- and genomic-based interventions and information to improve clients’ outcomes.
  • Collaborates with healthcare providers in providing genetic and genomic health care.
  • Collaborates with insurance providers and payers to facilitate reimbursement for genetic and genomic services.
  • Performs interventions and treatments appropriate to clients’ genetic and genomic healthcare needs.
  • Evaluates impact and effectiveness of genetic and genomic technology, information, interventions, and treatments on clients’ outcomes.

The RN
  • Identifies clients who may benefit from specific genetic and genomic information and services.
  • Identifies credible, accurate, appropriate, and current genetic and genomic information, resources, services, and technologies specific to given clients.
  • Identifies ethical, ethnic and ancestral, cultural, religious, legal, fiscal, and societal issues related to genetic and genomic information and technologies.
  • Defines issues that undermine the rights of all clients for autonomous, informed genetic- and genomic-related decision making and voluntary actions.

The RN facilitates referrals for specialized genetic and genomic services for clients as needed.

As we represent a small group of genetic professionals, we need to identify ourselves as key stakeholders in the strategic plan to implement these competencies. We need to be genetic and genomic educators on the clinical level, as well as the academic level. For further information, click here.


American Nurses Association. (2007). Genetics/genomics nursing: Scope and standards of practice. Washington, DC: Nursebooks.org.

Consensus Panel on Genetic/Genomic Nursing Competencies. (2006). Essential nursing competencies and curricula guidelines for genetics and genomics. Silver Spring, MD: American Nurses Association.

Jenkins, J., & Calzone, K.A. (2007). Establishing the essential nursing competencies for genetics and genomics. Journal of Nursing Scholarship, 1, 10–16.

Back to SIG Newsletter front page

Special Interest Group Newsletter  June 2007

News to Use From the NIH and NCI


Researchers Discover a Common Variation in a Gene Segment That Increases the Risk for Prostate Cancer

Researchers report that a common variation in a portion of DNA strongly predicts prostate cancer risk and may be responsible for as much as 20% of prostate cancer cases in white men in the United States. The gene variation was discovered on chromosome 8. The research was conducted by investigators from the National Cancer Institute, which is part of the National Institutes of Health, and partners in the Cancer Genetic Markers of Susceptibility (CGEMS) initiative. CGEMS researchers scanned the entire human genome to identify common, inherited gene mutations that increase the risk for breast and prostate cancers. The results appeared in the May 1, 2007, issue of Nature Genetics and were published online April 1, 2007.

The CGEMS study identified a region on chromosome 8 that is marked by a number of single nucleotide polymorphisms (SNPs), including rs6983267. SNPs are the most common type of gene variant, in which a single unit of DNA may vary from one person to the next. The rs6983267 SNP is located in a segment of DNA that has few known or predicted genes for prostate cancer.

The researchers confirmed that a previous finding of a different variant, marked by SNP rs1447295, also is associated with prostate cancer. The rs1447295 SNP is located nearby on the same arm of chromosome 8. The old and new susceptibility loci, or gene locations, appear to act independently, and changes in one region did not affect the degree of risk conferred by the other. The rs1447295 location could be responsible for about 7% of prostate cancer cases in white men of northern European descent. Thus, taken together with rs6983267, the two genetic changes could account for nearly one-quarter of the prostate cancer cases in white men.

CGEMS results were confirmed further by a number of other studies, including the American Cancer Society Cancer Prevention Study II, the Health Professionals Follow-up Study, the CeRePP French Prostate Case-Control Study, and the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Those studies combined enrolled 6,266 men.

Gleevec Decreases Cancer Recurrence for Patients With Primary Gastrointestinal Stromal Tumor

Preliminary results from a large, randomized, placebo-controlled clinical trial for patients with a primary gastrointestinal stromal tumor (GIST), a type of tumor usually found in the stomach or small intestine, showed that patients who received imatinib mesylate (Gleevec®, Novartis Oncology) after complete removal of their tumors were significantly less likely to have a recurrence of their cancer compared to those who did not receive imatinib. The clinical trial was sponsored by the National Cancer Institute, part of the National Institutes of Health, and conducted by a network of researchers led by the American College of Surgeons Oncology Group.

Researchers found that approximately 97% of patients in the study who received one year of imatinib after surgery did not have a recurrence of their cancer, compared to 83% of patients who received one year of placebo. Additionally, imatinib therapy was well tolerated by most patients enrolled in the study. The side effects observed in the trial were similar to those observed in other clinical trials with imatinib, such as nausea, diarrhea, and swelling. A presentation of detailed results from the trial is planned for a future scientific meeting.

Gleevec, which belongs to a class of agents that block cellular communication to prevent tumor growth, was approved by the U.S. Food and Drug Administration in 2002 for treatment of unresectable or metastatic GIST.

GIST is a sarcoma, which is a type of cancer that develops in the cells of the body’s connective or supportive tissues. GIST arises in the gastrointestinal tract. It is estimated that approximately 5,000–6,000 people are diagnosed with GIST each year in the United States.

American Cancer Society Issues New Guidelines for Breast Cancer Screening in Women at High Risk of Breast Cancer
Breast magnetic resonance imaging (MRI), in addition to mammography, is now recommended for women who are at high risk for breast cancer, and to improve detection of early breast cancer. An expert panel assembled by the American Cancer Society (ACS) concluded that sufficient evidence exists from nonrandomized screening trials and observational studies to support the recommendation for an annual breast MRI, in addition to annual mammography, in the following groups of women.

  • BRCA1/2 mutation carriers
  • Untested (i.e., mutation status unknown) first-degree relatives (mothers, sisters, and daughters) of BRCA1/2 carriers
  • Those with an estimated lifetime breast cancer risk of 20%–25% or greater, based largely on family history.
The expert panel also issued a consensus opinion, based on estimates of lifetime breast cancer risks, that an annual MRI and mammography be offered to women who have
  • Received radiation therapy treatments to the chest between ages 10 and 30.
  • Li-Fraumeni syndrome and their first-degree relatives.
  • Cowden and Bannayan-Riley-Ruvalcaba syndromes and their first-degree relatives.

Breast screening with MRI and mammography is recommended to begin at age 30 (or 5–10 years before the earliest previous breast cancer in the family, if prior to age 30) and to continue for as long as a woman is in good health. The newly revised breast cancer screening recommendations appear in the March/April 2007 issue of CA: A Cancer Journal for Clinicians (Saslow et al., 2007).

The expert panel examined the results of six major studies in the Netherlands, the United Kingdom, Canada, Germany, the United States, and Italy to determine the value of adding annual breast MRI to mammography for women who have an increased risk of breast cancer. Despite differences in patient population and MRI technique, all groups reported that MRI was much more effective in detecting breast cancer than mammography. Women with proven breast cancer had an abnormal MRI 71%–100% of the time. However, the women had an abnormal mammogram only 16%–40% of the time. Consequently, MRI was able to find many cancers that were missed by mammography. However, the greater ability of MRI to detect breast cancer comes with a tradeoff: MRI finds many more abnormalities that ultimately prove not to be cancer and do not require treatment. Women without breast cancer had a normal MRI only 81%–99% of the time, compared to 93%–99% of the time through mammography. Thus, MRI produces more "false alarms" than mammography, resulting in extra and unnecessary tests and biopsies, especially in the first year of MRI screening. In high-risk women who undergo breast biopsy after MRI, only 20%–40% of all biopsies reveal cancer.

The expert panel strongly recommends that MRI screenings be offered to women who are at high risk of developing breast cancer, in addition to, not instead of, mammography. With the combination of MRI and mammography, the ability to detect cancer while minimizing false alarms is greater than with MRI alone. The panel expressed concerns about high costs and limited availability of high-quality MRI breast screening services for women who are at high risk of developing breast cancer. The American College of Radiology (ACR) is developing an accreditation process for centers that perform breast MRI and MRI-guided biopsy. The ACR intends to have the MRI guideline available in late 2007. The National Cancer Institute has not joined in making the recommendation because the very high standard required for screening tests to be proven beneficial (i.e., firm evidence that the screening test reduces the death rate from breast cancer) has not yet been met. Meeting the standard requires larger studies that follow women over long periods of time, and such studies have not been done. Meanwhile, many experts believe that it is prudent to make reasoned recommendations based on what currently is known from the studies. The ACS panel represents the opinion of experts with special knowledge related to breast cancer screening. The experts have evaluated evidence that is currently available and have concluded that the benefits of MRI screening outweigh the risks for high-risk women.


Saslow, D., Boetes, C., Burke, W., Harms, S., Leach, M.O., Lehman, C.D., et al. (2007). American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA: A Cancer Journal for Clinicians, 57, 75–89.

Back to SIG Newsletter front page

Special Interest Group Newsletter  June 2007

Putting Evidence Into Practice

ONS Putting Evidence Into Practice (PEP) resources provide quick information about evidence-based interventions. Margaretta S. Page, MS, RN, primary author of the ONS PEP card on sleep-wake disturbances and its corresponding article in the Clinical Journal of Oncology Nursing, recounts her first-hand experience using the PEP resources. Click here for the article.

Back to SIG Newsletter front page

Special Interest Group Newsletter  June 2007

Membership Information

SIG Membership Benefits
  • Network with colleagues in an identified subspecialty area around the country.
  • Contribute articles for your SIG's newsletter.
  • Participate in discussions with other SIG members.
  • Contribute to the future path of the SIG.
  • Share your expertise.
  • Support and/or mentor a colleague.
  • Receive information about the latest advancements in treatments, clinical trials, etc.
  • Participate in ONS leadership by running for SIG coordinator-elect or join SIG work groups.
  • Acquire information with a click of a mouse at http://sig.vc.ons.org/, including
    • Educational opportunities for your subspecialty
    • Education material on practice
    • Calls to action
    • News impacting or affecting your specific SIG
    • Newsletters
    • Communiqués
    • Meeting minutes.

Join a Virtual Community
A great way to stay connected to your SIG is to join its Virtual Community. It's easy to do so. All you will need to do is

  • Log on to the ONS Web site (www.ons.org).
  • Select "Membership" from the tabs above.
  • Then, click on "Chapters, SIGs & Virtual Communities."
  • Scroll down to "Special Interest Groups (SIG) Virtual Community" and click.
  • Now, select "Find a SIG."
  • Locate and click on the name of your SIG from the list of all ONS SIGs displayed.
  • Once the front page of your SIG's Virtual Community appears on screen, select "New User" from the top left. (This allows you to create log-in credentials.)
  • Type the required information into the text fields as prompted.
  • Click "Join Group" (at the bottom right of the text fields) when done.
Special Notices
  • If you already have log-in credentials generated from the ONS Web site, use this information instead of attempting to generate new information.
  • If you created log-in credentials for the ONS Web site and wish to have different log-in information, you will not be able to use the same e-mail address to generate your new credentials. Instead, use an alternate e-mail address.

Subscribe to Your SIG's Virtual Community Discussion Forum
All members are encouraged to participate in their SIG's discussion forum. This area affords the opportunity for exchange of information between members and nonmembers on topics specific to all oncology subspecialties. Once you have your log-in credentials, you are ready to subscribe to your SIG's Virtual Community discussion forum. To do so,

  • Select "Log In," located next to "New User," and enter your information.
  • Next, click on the "Discussion" tab on the top right of the title bar.
  • Now, select "Featured Discussion" from the left drop-down menu.
  • Locate and select "Subscribe to Discussion" inside the "Featured Discussion" section.
  • Go to "Subscription Options" and select "Options."
  • When you have selected and entered all required criteria, you will receive a confirmation message.
  • Click "Finish."
  • You are now ready to begin participating in your SIG's discussion forum.
Participate in Your SIG's Virtual Community Discussion Forum
  • First, log in. (This allows others to identify you and enables you to receive notification [via e-mail] each time a response or new topic is posted.)
  • Click on "Discussion" from the top title bar.
  • Select "Featured Discussion" from the left drop-down menu.
  • Click on any posted topic to view contents and post responses.

Sign Up to Receive Your SIG's Virtual Community Announcements
As an added feature, members also are able to register to receive their SIG's announcements by e-mail.

  • From your SIG's Virtual Community page, locate the "Sign Up Here to Receive Your SIG's Announcements" section. This appears above the posted announcements section.
  • Select the "Click Here" feature, which will take you to a link to subscribe.
  • Once the "For Announcement Subscription Only" page appears on screen, select how you wish to receive your announcements.
    • As individual e-mails each time a new announcement is posted
    • One e-mail per day comprised of all new daily announcements posted
    • Opt-out, indicating that you will frequently browse your SIG's Virtual Community page for new postings
  • Enter your e-mail address.
  • Click on "Next Page."
  • Because you have already joined your SIG's Virtual Community, you will receive a security prompt with your registered user name already listed. Enter your password at this prompt and click "Finish."
  • This will bring up a listing of your SIG's posted announcements. Click on "My SIG's Page" to view all postings in their entirety or to conclude the registration process and begin browsing.
Back to SIG Newsletter front page

Special Interest Group Newsletter  June 2007

Cancer Genetics SIG Officers

Coordinator (2006-2008)
Jennifer Loud, RN, MSN, CRNP
Derwood, MD

Coordinator-Elect (2007-2008)
Lisa Aiello-Laws, RN, MSN, APN, C, APNG, AOCNS
Cape May, NJ

Millie Arnold, RN, OCN®, CCRC
Mesquite, TX


Patricia Herman, MSN, RN, AOCN®
Bethlehem, PA

Patricia Kelly, RN, MS, AOCN®
Dallas, TX

Copy Editor
Keightley Amen, BA

Know someone who would like to receive a print copy of this newsletter?
To print a copy of this newsletter from your home or office computer, click here or on the printer icon located on the SIG Newsletter front page. Print copies of each online SIG newsletter also are available through the ONS National Office. To have a copy mailed to you or another SIG member, contact Membership/Leadership Administrative Assistant Carol DeMarco at cdemarco@ons.org or 866-257-4ONS, ext. 6230.

To view past newsletters, click here.

ONS Membership/Leadership Team Contact Information

Angie Stengel, MS, CAE, Director of Membership/Leadership

Diane Scheuring, MBA, CMP, Manager of Member Services

Carol DeMarco, Membership/Leadership Administrative Assistant

The Oncology Nursing Society (ONS) does not assume responsibility for the opinions expressed and information provided by authors or by Special Interest Groups (SIGs). Acceptance of advertising or corporate support does not indicate or imply endorsement of the company or its products by ONS or the SIG. Web sites listed in the SIG newsletters are provided for information only. Hosts are responsible for their own content and availability.

Oncology Nursing Society
125 Enterprise Dr.
Pittsburgh, PA 15275-1214

Back to SIG Newsletter front page